Drug Trial Radar · NCT01484119
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
630
Actual
Start
Dec 2011
Primary completion
Feb 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions
- Seasonal Allergic Rhinitis
Interventions
ACT-129968Drug
daily tablets
PlaceboDrug
matching placebo tablets and capsules
CetirizineDrug
daily capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change in Daytime Nasal Symptom ScoreTime frame: baseline to end of treatment period (2 weeks)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Clinical Investigative Site 7905
Austin, Texas
Clinical Investigative Site 7907
Kerrville, Texas
Clinical Investigative Site 7903
New Braunfels, Texas
Clinical Investigative Site 7901
San Antonio, Texas
Clinical Investigative Site 7902
San Antonio, Texas
Clinical Investigative Site 7904
San Antonio, Texas
Clinical Investigative Site 7906
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.